Valsartan in Elderly Isolated Systolic Hypertension
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3,079
- 试验地点
- 2
- 主要终点
- composite cardiovascular events
研究概览
简要总结
The aim of this study is to compare the incidence of cardiovascular events between two target systolic blood pressure levels, below 140 mmHg and below 150 mmHg under treatment with valsartan in elderly isolated systolic hypertensive patients in Japan.
详细描述
Although antihypertensive therapy has been proven to reduce cardiovascular morbidity and mortality, it is unclear how much blood pressure should be decreased in elderly patients with hypertension. The Valsartan in Elderly Isolated Systolic Hypertension (VALISH) study is a multicenter parallel-group study comparing the incidence of cardiovascular events between two target systolic blood pressure levels, below 140 mmHg and below 150 mmHg, under treatment with valsartan, an angiotensin II receptor blocker, as an initial antihypertensive drug in elderly patients with isolated systolic hypertension. The number of patients to be recruited is 3,000 and the duration of follow-up is at least 2 years. This 3,000-patient trial was designed with a two-sided α level of 0.05 and 80% power to detect the difference in incidence of cardiovascular events between the target blood pressure levels based on estimation of the cardiovascular events ratio as 21.5/1,000 patient-years and 29.1/1,000 patient-years for the two blood pressure levels. The VALISH study, a large-scale investigator-initiated trial in Japan, will determine whether age should be considered in setting target blood pressure in treatment of isolated systolic hypertension in elderly patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 85 Years（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatients aged over 70 years and less than 85 years, regardless of sex.
- •Patients with stable seated systolic blood pressure of over 160 mmHg and diastolic blood pressure of less than 90 mmHg at two visits within 2 to 4 weeks.
- •Previously untreated patients or patients who are on other therapy that can be converted to valsartan.
排除标准
- •Patients with secondary hypertension or malignant hypertension.
- •Patients with seated systolic blood pressure of over 200 mmHg.
- •Patients with seated diastolic blood pressure of over 90 mmHg.
- •Patients with a history of cerebrovascular disorder or myocardial infarction within 6 months prior to enrolment in the study.
- •Patients who underwent coronary arterioplasty within 6 months prior to enrolment in the study or patients who will undergo coronary arterioplasty within 6 months after entry.
- •Patients with severe heart failure (NYHA functional classification III and IV).
- •Patients with severe aortic stenosis or valvular disease.
- •Patients with atrial fibrillation, atrial flutter, or serious arrhythmia.
- •Patients with renal dysfunction with serum creatinine level of over 2 mg/dL.
- •Patients with serious liver dysfunction.
- •Patients with a history of hypersensitivity to valsartan.
- •Other patients who are judged to be inappropriate for the study by the investigator or sub-investigator.
结局指标
主要结局
composite cardiovascular events
时间窗: participants will be followed for the duration of the study, an expected median follow-up 3.07 years
sudden death, fatal or nonfatal stroke, fatal or nonfatal myocardial infarction, death because of heart failure, other cardiovascular death, unplanned hospitalization for cardiovascular disease, and renal dysfunction (doubling of serum creatinine to a level 2.0 mg per 100 mL or introduction of dialysis).
次要结局
- sudden death(participants will be followed for the duration of the study, an expected median follow-up 3.07 years)
- renal disorder(participants will be followed for the duration of the study, an expected median follow-up 3.07 years)
- heart failure(participants will be followed for the duration of the study, an expected median follow-up 3.07 years)
- stroke(participants will be followed for the duration of the study, an expected median follow-up 3.07 years)
- myocardial infarction(participants will be followed for the duration of the study, an expected median follow-up 3.07 years)
- hospitalization(participants will be followed for the duration of the study, an expected median follow-up 3.07 years)
研究者
Hiromi Rakugi, MD, PhD
Professor
Osaka University